February 15, 2005 -- By the end of the day, the Centient Biotech 200™ gave up almost all of its early gains, hanging on to a tiny upward move by rising 2 points to 3383.62, a .06% increase. That number was less than the NYSE Composite, which gained .32%, or the Nasdaq, which climbed .30%. However, during the day, the big news was on the downside. Aphton got cut nearly in half after failing a Phase III trial, even though the company put a positive spin on the numbers, Teva beat estimates and fell anyway, Vical did much the same, except that its loss was lower than expected, CuraGen will license another antibody target from Seattle Genetics, which didn’t help the stock of either company, but Cerus and Immtech both managed to make significant moves higher. We give details...
